Business Context and Reporting Period
Creative Medical Technology Holdings, Inc., a Nevada corporation, filed this Form 8-K on May 8, 2018. The company is an emerging growth company focused on medical technology, specifically stem cell procedures.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding specific corporate events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The report details two significant corporate announcements made on May 8, 2018:
- Dr. Alexander Gershman is scheduled to attend the American Urological Association conference to discuss the CaverStem TM Stem Cell Procedure for drug-refractory erectile dysfunction.
- The company filed patent application number 62663912 covering the use of its AmnioStem TM stem cells to reduce or reverse natural aging.
Guidance, Outlook, and Risks
The press releases furnished as exhibits to this filing contain forward-looking statements based on information available as of the date made. Management warns that actual results could differ materially due to various factors, including those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. The company assumes no obligation to update these statements unless required by law.
Investor Verification Checklist
- Verify the status and potential commercial viability of patent application 62663912 regarding AmnioStem TM.
- Review the outcomes of Dr. Gershman's presentation at the American Urological Association conference.
- Consult the most recent Form 10-K and subsequent reports for detailed financial health and risk factors not included in this 8-K.
- Confirm the regulatory status of the CaverStem TM and AmnioStem TM procedures with relevant health authorities.